|
KR20200072389A
|
|
A novel compound and a pharmaceutical composition for treating neurological disorder comprising the same
|
|
KR102109168B1
|
|
A novel compound and a pharmaceutical composition for treating fungal infections
|
|
KR102126721B1
|
|
Novel Enterobacter aerogenes bacteriophage Ent-AEP-1 and its use for preventing proliferation of Enterobacter aerogenes and Enterobacter cloacae
|
|
US2019359948A1
|
|
Novel pseudomonas aeruginosa bacteriophage pse-aep-3 and use thereof for inhibiting proliferation of pseudomonas aeruginosa
|
|
CN110621775A
|
|
Novel pseudomonas aeruginosa bacteriophage Pse-AEP-4 and use thereof for inhibiting proliferation of pseudomonas aeruginosa
|
|
MX2018008545A
|
|
An antibacterial composition and a method of treating staphylococcal infections with the antibacterial composition.
|
|
CN108179136A
|
|
Coliphage Esc-COP-9 and its enteropathogenic E. Coli Proliferation Ability purposes
|
|
CN108179135A
|
|
Coliphage Esc-COP-7 and its enteropathogenic E. Coli Proliferation Ability purposes
|
|
WO2015020345A1
|
|
Method for preventing and treating clostridium perfringens infection
|
|
EP2981294A1
|
|
Metal oxide nanoparticle-based t1-t2 dual-mode magnetic resonance imaging contrast agent
|
|
WO2014163222A1
|
|
Metal oxide nanoparticle-based magnetic resonance imaging contrast agent with a central cavity
|
|
WO2013180316A1
|
|
Composition capable of improving stability of bacteriophage lysine proteins
|
|
WO2013035906A1
|
|
Method for preventing and treating salmonella typhimurium infection
|
|
US2013011369A1
|
|
Method for Prevention and Treatment of Salmonella Infection
|
|
EP2679247A1
|
|
Carboxylic mannan-coated contrast agent for magnetic resonance imaging
|
|
US2010203180A1
|
|
Antimicrobial protein derived from Podoviridae bacteriophage specific to Staphylococcus aureus
|
|
US2010203019A1
|
|
Podoviriedae bacteriophage having killing activity specific to Staphylococcus aureus
|
|
JP2007154399A
|
|
Tool for pack in form of glove
|
